Glutathione transferase isozyme genotypes in patients with prostate and bladder carcinoma
- Cite this article as:
- Steinhoff, C., Franke, K., Golka, K. et al. Arch Toxicol (2000) 74: 521. doi:10.1007/s002040000161
Genotype distributions for GSTP1, GSTM1, and GSTT1 were determined in 91 patients with prostatic carcinoma and 135 patients with bladder carcinoma and compared with those in 127 abdominal surgery patients without malignancies. None of the genotypes differed significantly with respect to age or sex among controls or cancer patients. In the group of prostatic carcinoma patients, GSTT1 null allele homozygotes were more prevalent (25% in carcinoma patients vs 13% in controls, Fisher P=0.02, χ2P=0.02, OR=2.31, CI=1.17–4.59) and the combined M1-/T1-null genotype was also more frequent (9% vs 3%, χ2P=0.02, Fisher P=0.03). Homozygosity for the GSTM1 null allele was more frequent among bladder carcinoma patients (59% in bladder carcinoma patients vs 45% in controls, Fisher P=0.03, χ2P=0.02, OR=1.76, CI=1.08–2.88). In contrast to a previous report, no significant increase in the frequency of the GSTP1b allele was found in the tumor patients. Except for the combined GSTM1-/T1-null genotype in prostatic carcinoma, none of the combined genotypes showed a significant association with either of the cancers. These findings suggest that specific single polymorphic GST genes, that is GSTM1 in the case of bladder cancer and GSTT1 in the case of prostatic carcinoma, are most relevant for the development of these urological malignancies among the general population in Central Europe.